Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drug
Eli Lilly has ended two mid-stage trials of an oral GLP-1 drug for obesity, according to updates this week to the US federal clinical trials database. Another Phase 2 study remains
View ArticleFTC and congressional oversight leader take aim at PBMs again
The Federal Trade Commission and House Oversight Committee Chair James Comer (R-KY) are re-upping their prior efforts to target the influence of the top PBMs' group purchasing organizations (GPOs) and...
View ArticleFDA approves Eisai and Biogen's subcutaneous Leqembi
The FDA approved a new formulation of Eisai and Biogen’s Alzheimer’s drug Leqembi, an incremental step in the companies’ strategy to compete with Eli Lilly’s Kisunla. The new formulation can be...
View ArticleFDA approves BTK inhibitor that’s key to Sanofi’s immunology strategy
The FDA approved Sanofi’s BTK inhibitor that the French drugmaker acquired in its $3.7 billion buyout of Principia Biopharma. The company said Friday that the regulators cleared rilzabrutinib in a rare...
View Article#ESC25: Cytokinetics says heart drug data could change standard of care
MADRID — Cytokinetics believes its cardiac myosin inhibitor aficamten could become the new standard of care in a heart muscle disorder following the release of full data from a late-stage trial. The...
View ArticleTurbulence at the CDC; How Scripps reinvented its financial model;...
Welcome to another edition of Endpoints Weekly, and happy Labor Day weekend! I’ve returned from vacation and am ready to help you get your weekend started. Let’s get into the headlines. We had a lot ...
View Article#ESC25: AstraZeneca aims for 2025 filing with 'best-in-class' hypertension pill
MADRID — Pivotal data on AstraZeneca’s blood pressure pill baxdrostat look good enough for approval, but competing in the market might be a harder ask as the company prepares for a potential match...
View Article#ESC25: Alnylam to kick off CV events trial of zilebesiran despite mid-stage...
MADRID — Alnylam Pharmaceuticals said it will start a Phase 3 cardiovascular outcomes trial of its hypertension therapy zilebesiran this year, despite data showing the drug failed in a mid-stage study....
View Article#ESC25: Ionis' study success in moderately high triglyceride levels raises...
MADRID — Ionis Pharmaceuticals’ Tryngolza reduced triglycerides in patients with moderately high levels of these fat molecules in a late-stage test, according to data presented Saturday at the annual...
View Article#ESC25: Novartis' Leqvio cuts lipid levels, muscle pain in high-risk...
MADRID — Novartis’ cholesterol-cutting medicine Leqvio swiftly improved high-risk patients’ lipid levels when added to standard of care, according to data presented Saturday at the annual meeting of...
View ArticleNvidia-backed Charm Therapeutics gets $80M to take AI-designed cancer drug to...
A biotech co-founded by Nobel laureate David Baker has reeled in an $80 million Series B to get into the clinic early next year with an AI-designed cancer drug. The London-based startup ...
View ArticleJohn Maraganore, Clive Meanwell team up again with $50M to prevent...
John Maraganore and Clive Meanwell have benefited greatly from the successes of their prior biopharma endeavors, having opened up the field of siRNAs with Alnylam Pharmaceuticals and Novartis-acquired...
View ArticleIonis says 'unprecedented' data support Tryngolza's label expansion in severe...
Ionis Pharmaceuticals’ Tryngolza has succeeded in two crucial late-stage tests that could considerably broaden the drug's commercial reach, the company said Tuesday. Ionis is mulling how to price the...
View ArticleExclusive: Neon Health raises $6M for AI to help patients access specialty drugs
San Francisco-based Neon Health just raised $6 million for AI tools that smooth out the many steps before a specialty medication can be issued, Endpoints News learned exclusively. NFX led the seed...
View ArticlePost-Hoc Live: What it takes to build a new biotech in 2025
If anybody knows the trials and tribulations of the biotech market, it’s John Maraganore and Clive Meanwell. Both the former longtime Alnylam CEO and former Medicines Company executive have been in the...
View ArticleArrowhead piques Novartis' neuro interest with $200M upfront deal
Arrowhead Pharmaceuticals has forged another alliance for its RNA therapies, this time collecting $200 million upfront from Novartis. The California biotech said Tuesday that the deal includes a...
View ArticleUpstream Bio's Phase 2 win could set it up as a potential Dupixent, Tezspire...
A biotech that braved the chilly IPO market to go public last year toplined its first dataset, earning a mid-stage win in an inflammatory disease. Upstream Bio’s program, known as verekitug, hit all of...
View ArticleEditas becomes latest gene editing company to turn to more common diseases
Editas Medicine has decided to pursue gene editing for hyperlipidemia, a condition of high cholesterol that impacts tens of millions of people in the US. It’s a substantial departure from Editas’...
View ArticleVertex enlists Enlaza for gene therapy conditioning and autoimmune disease pact
Vertex is recruiting Enlaza Therapeutics to make better conditioning drugs to pair with its sickle cell and thalassemia gene therapy Casgevy, and develop new treatments for autoimmune diseases. The...
View Article